NetworkNewsBreaks – Silo Pharma Inc. (SILO) Fusi
Post# of 137
(Total Views: 156)
Posted On: 08/25/2022 4:17:49 PM
NetworkNewsBreaks – Silo Pharma Inc. (SILO) Fusing Traditional Therapeutics with Psychedelic Research
Silo Pharma (OTCQB: SILO) recently reported that the University of California San Francisco (“UCSF”) had successfully administered psilocybin to a test group of Parkinson’s disease patients. The psilocybin was administered “as part of a scientific research agreement (‘SRA’) entered with Silo in June 2021 to ‘determine the effects of psilocybin on inflammatory markers of patients who have exhibited Parkinson’s, bipolar disorder and chronic back pain,’” a recent article reads. According to Silo Pharma CEO Eric Weisblum, the company is encouraged by the progress and looks forward to the next cohort of patients receiving therapeutic treatment and sharing the analysis of these markers when data has been analyzed and completed. “Scientific research is just beginning to recognize the potential of psychedelics to address the symptoms of numerous chronic diseases. Silo aims to catalyze the movement by fusing traditional therapeutics with psychedelic research to provide innovative treatments for fibromyalgia, post-traumatic stress disorder (‘PTSD’), chronic pain, rheumatoid arthritis, Parkinson’s, Alzheimer’s disease, and other rare neurological disorders. The company identifies and partners with leading medical universities, providing financial resources that propel cutting-edge research through the clinical stage and into commercialization.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Silo Pharma (OTCQB: SILO) recently reported that the University of California San Francisco (“UCSF”) had successfully administered psilocybin to a test group of Parkinson’s disease patients. The psilocybin was administered “as part of a scientific research agreement (‘SRA’) entered with Silo in June 2021 to ‘determine the effects of psilocybin on inflammatory markers of patients who have exhibited Parkinson’s, bipolar disorder and chronic back pain,’” a recent article reads. According to Silo Pharma CEO Eric Weisblum, the company is encouraged by the progress and looks forward to the next cohort of patients receiving therapeutic treatment and sharing the analysis of these markers when data has been analyzed and completed. “Scientific research is just beginning to recognize the potential of psychedelics to address the symptoms of numerous chronic diseases. Silo aims to catalyze the movement by fusing traditional therapeutics with psychedelic research to provide innovative treatments for fibromyalgia, post-traumatic stress disorder (‘PTSD’), chronic pain, rheumatoid arthritis, Parkinson’s, Alzheimer’s disease, and other rare neurological disorders. The company identifies and partners with leading medical universities, providing financial resources that propel cutting-edge research through the clinical stage and into commercialization.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)SILO Pharma Inc. (SILO) Stock Research Links
Scroll down for more posts ▼